Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers

We began analyzing https://link.springer.com/chapter/10.1007/978-1-4419-9129-4_2, but it redirected us to https://link.springer.com/chapter/10.1007/978-1-4419-9129-4_2. The analysis below is for the second page.

Title[redir]:
Clinical Aspects of Bone Metastases in Prostate Cancer | SpringerLink
Description:
Bone is the second most common site of metastases in human cancer. At least two-thirds of the approximately 553,400 Americans who die from cancer each year have bone metastases (Greenlee et al., 2001). Prostate, breast, and lung cancers account for at least 80% of...

Matching Content Categories {πŸ“š}

  • Education
  • Health & Fitness
  • Science

Content Management System {πŸ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 9,240,649 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We don’t know how the website earns money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {πŸ”}

google, scholar, cancer, cas, pubmed, prostate, article, journal, bone, metastases, clinical, oncology, metastatic, urology, skeletal, patients, research, growth, treatment, metastasis, carcinoma, trial, chapter, medicine, study, factor, human, advanced, cells, prostatic, randomized, university, keller, disease, american, chung, radiotherapy, therapy, smith, phase, privacy, cookies, content, european, information, publish, biology, breast, lipton, pamidronate,

Topics {βœ’οΈ}

2-[f-18]fluoro-2-deoxy-d-glucose 2-deoxy-2-[f-18] fluoro-d-glucose double-blind randomised trial prostate-derived growth factors weekly high-dose calcitriol radiation therapy-message conveyed advanced androgen-independent carcinoma serum prostate-specific antigen peptide-bound collagen type androgen-independent prostate cancer cross-links n-telopeptide androgen-independent cancer progression growth factor receptor placebo-controlled trial chapter tu privacy choices/manage cookies hormone refractory disease phase ii study spinal cord compression receptor antagonist atrasetan proteasome inhibitor ps-341 external radiation therapy prostate specific antigen download preview pdf stromal-epithelial interaction orchiectomy versus goserelin low dose dexamethasone symptomatic osseous metastasis increased bone resorption external beam radiotherapy advanced prostatic carcinoma population-based study relapsed/refractory disease preoperative plasma levels human prostate cancer prostatic osteoblastic factor osteoblast-stimulating factor metastatic prostate cancer circulating prostate cells pyridinium cross-links clinically localized adenocarcinoma prostate cancer metastasis metastatic bone cancer bone-targeted therapy metastatic bone disease decreases skeletal complications reducing skeletal events chapter cite symptomatic osseous metastases tyrosine kinases expressed

Schema {πŸ—ΊοΈ}

ScholarlyArticle:
      headline:Clinical Aspects of Bone Metastases in Prostate Cancer
      pageEnd:46
      pageStart:23
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-4419-9129-4.jpg
      genre:
         Medicine
         Medicine (R0)
      isPartOf:
         name:The Biology of Skeletal Metastases
         isbn:
            978-1-4419-9129-4
            978-1-4613-4803-0
         type:Book
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Shi-Ming Tu
            affiliation:
                  name:The University of Texas, M.D. Anderson Cancer Center
                  address:
                     name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sue-Hwa Lin
            affiliation:
                  name:The University of Texas, M.D. Anderson Cancer Center
                  address:
                     name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
                  name:The University of Texas, M.D. Anderson Cancer Center
                  address:
                     name:Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:Prostate Cancer, Bone Metastasis, Radical Prostatectomy, Zoledronic Acid, Metastatic Prostate Cancer
      description:Bone is the second most common site of metastases in human cancer. At least two-thirds of the approximately 553,400 Americans who die from cancer each year have bone metastases (Greenlee et al., 2001). Prostate, breast, and lung cancers account for at least 80% of the skeletal metastases. Tumors arising in the prostate and breast are particularly prone to disseminate to bone; up to 85% of patients with these cancers have evidence of bone metastases at autopsy. Carcinomas of the lung, thyroid, and kidney also commonly spread to the bone (30–40%). However, tumors of the gastrointestinal tract rarely metastasize to the bone (5%) (Galasko, 1986).
      datePublished:2004
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:The Biology of Skeletal Metastases
      isbn:
         978-1-4419-9129-4
         978-1-4613-4803-0
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The University of Texas, M.D. Anderson Cancer Center
      address:
         name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas, M.D. Anderson Cancer Center
      address:
         name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:The University of Texas, M.D. Anderson Cancer Center
      address:
         name:Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Shi-Ming Tu
      affiliation:
            name:The University of Texas, M.D. Anderson Cancer Center
            address:
               name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Sue-Hwa Lin
      affiliation:
            name:The University of Texas, M.D. Anderson Cancer Center
            address:
               name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
            name:The University of Texas, M.D. Anderson Cancer Center
            address:
               name:Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
      name:Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
      name:Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {πŸ”—}(302)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com
7.93s.